Takeda Historical Cash Flow
| TAK Stock | USD 15.05 0.09 0.59% |
Analysis of Takeda Pharmaceutical cash flow over time is an excellent tool to project Takeda Pharmaceutical future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 580.5 B or Total Cash From Operating Activities of 433.7 B as it is a great indicator of Takeda Pharmaceutical ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Takeda Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Takeda Pharmaceutical is a good buy for the upcoming year.
Takeda |
About Takeda Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Takeda balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Takeda's non-liquid assets can be easily converted into cash.
Takeda Pharmaceutical Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Takeda Pharmaceutical to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Takeda Pharmaceutical operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Takeda Pharmaceutical's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Takeda Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At this time, Takeda Pharmaceutical's Net Income is quite stable compared to the past year. End Period Cash Flow is expected to rise to about 626.2 B this year, although the value of Change In Working Capital is projected to rise to (279.7 B).
Takeda Pharmaceutical cash flow statement Correlations
Click cells to compare fundamentals
Takeda Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Takeda Pharmaceutical cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | 26.0B | (46.1B) | (79.2B) | (115.7B) | (104.2B) | (99.0B) | |
| Change In Cash | 328.6B | (116.5B) | (316.2B) | (75.7B) | (68.2B) | (64.7B) | |
| Free Cash Flow | 774.5B | 937.1B | 343.5B | 235.6B | 271.0B | 295.4B | |
| Change In Working Capital | 275.8B | 98.6B | (25.3B) | (256.0B) | (294.4B) | (279.7B) | |
| Begin Period Cash Flow | 637.6B | 966.2B | 849.7B | 533.5B | 480.2B | 617.5B | |
| Other Cashflows From Financing Activities | (35.0B) | 140.7B | (2.7B) | (66.4B) | (76.4B) | (72.6B) | |
| Depreciation | 559.7B | 583.2B | 664.4B | 728.0B | 837.2B | 879.1B | |
| Other Non Cash Items | (228.4B) | 95.4B | (97.7B) | 120.8B | 138.9B | 145.9B | |
| Dividends Paid | 283.4B | 283.7B | 279.4B | (287.2B) | (330.3B) | (313.8B) | |
| Capital Expenditures | 236.5B | 186.0B | 633.7B | 480.7B | 552.8B | 580.5B | |
| Total Cash From Operating Activities | 1.0T | 1.1T | 977.2B | 716.3B | 823.8B | 433.7B | |
| Net Income | 376.2B | 230.2B | 317.0B | 144.1B | 129.7B | 217.6B | |
| Total Cash From Financing Activities | (1.1T) | (1.1T) | (709.1B) | (354.4B) | (319.0B) | (303.0B) | |
| End Period Cash Flow | 966.2B | 849.7B | 533.5B | 457.8B | 412.0B | 626.2B | |
| Sale Purchase Of Stock | (2.1B) | (77.5B) | (26.9B) | (2.3B) | (2.7B) | (2.8B) | |
| Change To Account Receivables | (9.3B) | 127.3B | 75.1B | 15.1B | 17.4B | 18.2B | |
| Stock Based Compensation | 37.7B | 43.4B | 60.7B | 70.9B | 81.5B | 85.6B | |
| Investments | 62.0B | (198.1B) | (607.1B) | (463.9B) | (417.5B) | (438.3B) | |
| Net Borrowings | (586.1B) | (660.5B) | (600.5B) | (285.1B) | (256.6B) | (243.7B) | |
| Total Cashflows From Investing Activities | 292.1B | 393.5B | (198.1B) | (607.1B) | (546.4B) | (573.7B) | |
| Change To Operating Activities | 44.5B | 222.5B | (66.3B) | 63.6B | 73.1B | 76.8B | |
| Other Cashflows From Investing Activities | (8.9B) | (1.0B) | 26.6B | (251.7B) | (226.5B) | (215.2B) | |
| Change To Netincome | (75.3B) | (200.5B) | 169.9B | 21.0B | 24.2B | 25.4B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.78) | Dividend Share 192 | Earnings Share 0.43 | Revenue Per Share | Quarterly Revenue Growth 0.03 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.